Immunome (IMNM) Other Accumulated Expenses (2020 - 2026)

Immunome's Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• Quarterly Other Accumulated Expenses fell 74.51% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 74.51% YoY) and the FY2025 annual result came in at $3.6 million, down 54.55% from the prior year.
• Other Accumulated Expenses was $3.2 million for Q1 2026 at Immunome, down from $3.6 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $15.6 million in Q3 2025 and bottomed at $55000.0 in Q1 2024.
• A 5-year average of $4.5 million and a median of $2.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses sank 97.24% — and 2025, when it soared 22547.27%.
• Immunome's Other Accumulated Expenses stood at $86000.0 in 2022, then soared by 751.16% to $732000.0 in 2023, then soared by 989.89% to $8.0 million in 2024, then slumped by 54.55% to $3.6 million in 2025, then fell by 12.44% to $3.2 million in 2026.
• Business Quant data shows IMNM's Other Accumulated Expenses at $3.2 million in Q1 2026, $3.6 million in Q4 2025, and $15.6 million in Q3 2025.